Journal
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
Volume 47, Issue 1, Pages 237-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ecl.2017.10.006
Keywords
Diabetes mellitus; Chronic kidney disease; Cardiovascular risk factors; Glycated albumin; Fructosamine; A1C; Dyslipidemia of chronic kidney disease
Categories
Funding
- Eli Lilly
- Takeda
- Novo Nordisk
- Sanofi- Aventis
- Astra- Zeneca
- Abbott
- Boehringer Ingelheim
- Novo- Nordisk
- Asahi
- Sanofi
- Bayer
- Lexicon
- Tullis Tulane Alumni Chair in Diabetes
- Patient Centered Outcomes Research Institute (through Louisiana Clinical Data Research Network [LACDRN])
- National Institute of General Medical Sciences of the National Institutes of Health [1 U54 GM104940]
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD043451] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM104940] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The authors discuss mechanisms of increased cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) and strategies for managing cardiovascular (CV) risk in these patients. Their focus was mainly on decreasing CV events and progression of microvascular complications by reducing levels of glucose and lipids. The authors searched PubMed with no limit on the date of the article. All articles were discussed among all authors. They chose pertinent articles and searched their references in turn for additional relevant publications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
